Poly (ADP-Ribose) Polymerase-1 (PARP1) Deficiency and Pharmacological Inhibition by Pirenzepine Protects From Cisplatin-Induced Ototoxicity Without Affecting Antitumor Efficacy

Poly (ADP-Ribose) Polymerase-1 (PARP1) Deficiency and Pharmacological Inhibition by Pirenzepine Protects From Cisplatin-Induced Ototoxicity Without Affecting Antitumor Efficacy

Cisplatin remains an indispensable drug for the systemic treatment of many solid tumors. However, a major dose-limiting side-effect is ototoxicity. In some scenarios, such as treatment of germ cell tumors or adjuvant therapy of non-small cell lung cancer, cisplatin cannot be replaced without undue l...

Full description

Bibliographic Details
Main Authors: Anke Tropitzsch, Marcus Müller, François Paquet-Durand, Frank Mayer, Hans-Georg Kopp, Andre Schrattenholz, Andrea Müller, Hubert Löwenheim
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Cellular Neuroscience
Subjects:
cisplatin
ototoxicity
otoprotection
organ culture
PARP
hair cell loss
Online Access:https://www.frontiersin.org/article/10.3389/fncel.2019.00406/full

Internet

https://www.frontiersin.org/article/10.3389/fncel.2019.00406/full

Similar Items